AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
Phase 3positiveRepathaPositive
AI Analysis
Summary
Amgen announced that Repatha demonstrated reduction in mortality risk from all causes in high-risk primary prevention patients in a Phase 3 trial, making it the first and only PCSK9 inhibitor with this clinical benefit in this patient population.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Repatha reduced risk of death from all causes in high-risk primary prevention patients
Importance:8/10
Sentiment:
0.85
PCSK9 inhibitorcardiovascularprimary preventionmortality benefitfirst-to-market
Related Companies
Read the original article
Published by PR Newswire Pharma on August 31, 2026 7:18 AM